# A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates

> **NCT06632990** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Allyx Therapeutics** · enrollment: 36 (estimated)

## Conditions studied

- Drug Drug Interaction (DDI)

## Interventions

- **DRUG:** BMS-984923
- **DRUG:** Midazolam
- **DRUG:** Caffeine
- **DRUG:** dextromethorphan

## Key facts

- **NCT ID:** NCT06632990
- **Lead sponsor:** Allyx Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-04
- **Primary completion:** 2025-04-03
- **Final completion:** 2025-10-15
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-02-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06632990

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06632990, "A Study Evaluating the Potential of BMS-984923 to Alter the Systemic Exposure of Three Orally Administered Probe Substrates". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06632990. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*